TNF and COVID-19: Trials targeting other inflammatory mediators are underway, although, surprisingly, the most abundantly used anti-inflammatory monoclonal antibodies, which target TNF and have been used in over 10 million autoimmune disease patients to date, have not yet been definitively evaluated for COVID-19 (71, , –74).